Skip to main content

NICE

Volume 454: debated on Monday 11 December 2006

To ask the Secretary of State for Health what assessment she has made of the effect on her Department's expenditure of the National Institute for Health and Clinical Excellence's decision to withdraw eligibility of those suffering from the early stages of Alzheimer's disease to have the drugs (a) Donepezil, (b) Rivastigmine and (c) Galantamine prescribed on the NHS. (101129)

I have been asked to reply.

Changes in the prescribing arrangements for people in the early stages of Alzheimer's disease are unlikely to have any effects on the Department's expenditure.